Pharmacogenomic testing for angiotensin-converting enzyme inhibitors: Getting ready for prime time

Pharmacogenomics

Volumn 11, Issue 10, 2010, Pages 1345-1348

  Denus, Simon De ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

angiotensin converting enzyme inhibitor; atherosclerosis; blood pressure; hypertension; pharmacogenomics

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; APELIN RECEPTOR; BRADYKININ B1 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PERINDOPRIL;

CARDIOVASCULAR EFFECT; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE INSERTION; GENETIC MARKER; GENOTYPE; HUMAN; PHARMACOGENOMICS; PHENOTYPE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSIENT ISCHEMIC ATTACK; UNSPECIFIED SIDE EFFECT;

EID: 78149314268     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.124     Document Type: Editorial

References (22)

1. Erdos EG, Tan F, Skidgel RA: Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function. Hypertension 55(2), 214-220 (2010).
2. Brunner M, Cooper-Dehoff RM, Gong Y et al.: Factors infuencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study). Am. J. Cardiol. 99(11), 1549-1554 (2007).
3. de Denus S, Tardif JC, White M et al.: Quantifcation of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective ana lysis of the studies of left ventricular dysfunction (SOLVD) trials. Am. Heart J. 152(4), 705-712 (2006).
4. Vinck WJ, Fagard RH, Vlietinck R, Lijnen P: Heritability of plasma renin activity and plasma concentration of angiotensinogen and angiotensin-converting enzyme. J. Hum. Hypertens. 16(6), 417-422 (2002).
5. Brugts JJ, Boersma E, Simoons ML: Tailored-therapy of ACE-inhibitors in stable CAD: pharmacogenetic profling of treatment beneft. Pharmacogenomics 11(8), 1115-1126 (2010).
6. Fox KM: Effcacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362(9386), 782-788 (2003).
7. PROGRESS collaborative group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358(9287), 1033-1041 (2001).
8. de Denus S, Zakrzewski-Jakubiak M, Dube MP et al.: Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan. Ann. Pharmacother. 42(7), 925-932 (2008).
9. Kurland L, Hallberg P, Melhus H et al.: The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish irbesartan left ventricular hypertrophy investigation vs. Atenolol (SILVHIA) trial. Am. J. Hypertens. 21(7), 836-839 (2008).
10. Su X, Lee L, Li X et al.: Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor. Circulation 115(6), 725-732 (2007).
11. Nordestgaard BG, Kontula K, Benn M et al.: Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study. Pharmacogenet. Genomics 20(2), 77-85 (2010).
12. Fan X, Wang Y, Sun K et al.: Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of captopril in women. Clin. Pharmacol. Ther. 82(2), 187-196 (2007).
13. Lynch AI, Boerwinkle E, Davis BR et al.: Antihypertensive pharmacogenetic effect of fbrinogen-b variant-455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study. Pharmacogenet. Genomics 19(6), 415-421 (2009).
14. Brugts JJ, De Maat MP, Boersma E et al.: The rationale and design of the perindopril genetic association study (PERGENE): a pharmacogenetic ana lysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease. Cardiovasc. Drugs Ther. 23(2), 171-181 (2009).
15. Arnett DK, Davis BR, Ford CE et al.: Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the genetics of hypertension-associated treatment (GenHAT) study. Circulation 111(25), 3374-3383 (2005).
16. Harrap SB, Tzourio C, Cambien F et al.: The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefts of ACE inhibition. Hypertension 42(3), 297-303 (2003).
17. Johnson AD, Gong Y, Wang D et al.: Promoter polymorphisms in ACE (angiotensin I-converting enzyme) associated with clinical outcomes in hypertension. Clin. Pharmacol. Ther. 85(1), 36-44 (2009).
18. Franks PW: Identifying genes for primary hypertension: methodological limitations and gene-environment interactions. J. Hum. Hypertens. 23(4), 227-237 (2009).
19. Taylor R: Conundrum of the HOPE study: time of taking ramipril may account for lack of relation between blood pressure and outcome. BMJ 327(7416), 681-682, author reply 682 (2003).
20. Yusuf S, Bosch J, Sleight P: Preventing stroke with ramipril-authors' reply. BMJ 326(7379), 52 (2003).
21. Goyal D, Chong AY, Watson RL, Prasad N, Watson RD: Assessment of single versus twice daily dosing of ramipril by ambulatory blood pressure monitoring in patients similar to those included in the hope study. J. Hum. Hypertens. 21(7), 525-530 (2007).
22. Messerli FH, Weber MA: ALLHAt-all hit or all miss? Key questions still remain. Am. J. Cardiol. 92(3), 280-281 (2003).